Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term open-label follow-up extending to approximately one year. The trial design meets the highest standard of clinical evidence, making its efficacy and safety findings particularly meaningful for patients who have not responded adequately to conventional treatments.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally with inadequate pharmacologic alternatives. The large sample size (820 participants) and robust design with extended follow-up strengthen the reliability of efficacy and safety data, which is essential for informing clinical practice guidelines and regulatory decision-making in this emerging therapeutic area. Given the opioid crisis and limitations of current CLBP treatments, demonstration of a safe and effective cannabis extract could substantially alter treatment algorithms and provide clinicians with a validated non-opioid option.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of VER-01, a full-spectrum cannabis extract, addresses a genuine clinical need in chronic low back pain management where conventional options have limited efficacy and significant side effect profiles. While the study’s size and randomized design are commendable, the efficacy signal will depend critically on whether clinically meaningful pain reduction was achieved and sustained through the open-label extension phase, as well as how adverse events compared to standard care rather than placebo alone. Key confounders to consider include the heterogeneity of CLBP etiologies, variable cannabinoid content and standardization across batches, and potential response bias in the open-label portion that may inflate perceived benefit. Practitioners should await publication of the full results including effect sizes, durability data, and comparative safety profiles before incorporating this into routine practice, but the trial design suggests a more rigorous evidence base than currently exists for most cannabis-based pain interventions. If efficacy is confirmed in opioid-sparing or adjunctive contexts
| |